These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 25616657)

  • 21. Radiographic and Hormonal Regression in Prolactinomas: An Analysis of Treatment Failure.
    Akinduro OO; Lu VM; Izzo A; De Biase G; Vilanilam G; Van Gompel JJ; Bernet V; Donaldson A; Olomu O; Meyer FB; Quinones-Hinojosa A; Chaichana KL
    World Neurosurg; 2019 Sep; 129():e686-e694. PubMed ID: 31181361
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Diagnosis and drug therapy of prolactinoma.
    Ciccarelli E; Camanni F
    Drugs; 1996 Jun; 51(6):954-65. PubMed ID: 8736617
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Temozolomide treatment of a pituitary carcinoma and two pituitary macroadenomas resistant to conventional therapy.
    Hagen C; Schroeder HD; Hansen S; Hagen C; Andersen M
    Eur J Endocrinol; 2009 Oct; 161(4):631-7. PubMed ID: 19654234
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Successful treatment of leptomeningeally metastasised pituitary carcinoma with temozolomide.
    van der Vlist A; Snijders TJ; Stades AME; Spliet WGM; De Vos FYFL
    Neth J Med; 2017 Dec; 75(10):451-454. PubMed ID: 29256415
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Temozolomide treatment can improve overall survival in aggressive pituitary tumors and pituitary carcinomas.
    Lasolle H; Cortet C; Castinetti F; Cloix L; Caron P; Delemer B; Desailloud R; Jublanc C; Lebrun-Frenay C; Sadoul JL; Taillandier L; Batisse-Lignier M; Bonnet F; Bourcigaux N; Bresson D; Chabre O; Chanson P; Garcia C; Haissaguerre M; Reznik Y; Borot S; Villa C; Vasiljevic A; Gaillard S; Jouanneau E; Assié G; Raverot G
    Eur J Endocrinol; 2017 Jun; 176(6):769-777. PubMed ID: 28432119
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A novel use of temozolomide in a patient with malignant prolactinoma.
    Byrne S; Karapetis C; Vrodos N
    J Clin Neurosci; 2009 Dec; 16(12):1694-6. PubMed ID: 19818629
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pituitary atypical adenoma or carcinoma sensitive to temozolomide combined with radiation therapy: a case report of early identification and management.
    Zhong C; Yin S; Zhou P; Jiang S
    Turk Neurosurg; 2014; 24(6):963-6. PubMed ID: 25448217
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inhibition of PI3K/AKT/mTOR pathway enhances temozolomide-induced cytotoxicity in pituitary adenoma cell lines in vitro and xenografted pituitary adenoma in female nude mice.
    Dai C; Zhang B; Liu X; Ma S; Yang Y; Yao Y; Feng M; Bao X; Li G; Wang J; Guo K; Ma W; Xing B; Lian W; Xiao J; Cai F; Zhang H; Wang R
    Endocrinology; 2013 Mar; 154(3):1247-59. PubMed ID: 23384836
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Aggressive pituitary tumours: the role of temozolomide and the assessment of MGMT status.
    McCormack AI; Wass JA; Grossman AB
    Eur J Clin Invest; 2011 Oct; 41(10):1133-48. PubMed ID: 21496012
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rapid decrease in amino acid metabolism in prolactin-secreting pituitary adenomas after bromocriptine treatment: a PET study.
    Bergström M; Muhr C; Lundberg PO; Bergström K; Gee AD; Fasth KJ; Långström B
    J Comput Assist Tomogr; 1987; 11(5):815-9. PubMed ID: 3498743
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment of pituitary neoplasms with temozolomide: a review.
    Syro LV; Ortiz LD; Scheithauer BW; Lloyd R; Lau Q; Gonzalez R; Uribe H; Cusimano M; Kovacs K; Horvath E
    Cancer; 2011 Feb; 117(3):454-62. PubMed ID: 20845485
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term control of a MEN1 prolactin secreting pituitary carcinoma after temozolomide treatment.
    Philippon M; Morange I; Barrie M; Barlier A; Taieb D; Dufour H; Conte-Devolx B; Brue T; Castinetti F
    Ann Endocrinol (Paris); 2012 Jun; 73(3):225-9. PubMed ID: 22520146
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The neurosurgical management of prolactinomas.
    Gökalp HZ; Deda H; Attar A; Uğur HC; Arasil E; Egemen N
    J Neurosurg Sci; 2000 Sep; 44(3):128-32. PubMed ID: 11126446
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Temozolomide responsiveness in aggressive corticotroph tumours: a case report and review of the literature.
    Annamalai AK; Dean AF; Kandasamy N; Kovacs K; Burton H; Halsall DJ; Shaw AS; Antoun NM; Cheow HK; Kirollos RW; Pickard JD; Simpson HL; Jefferies SJ; Burnet NG; Gurnell M
    Pituitary; 2012 Sep; 15(3):276-87. PubMed ID: 22076588
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term outcome and MGMT as a predictive marker in 24 patients with atypical pituitary adenomas and pituitary carcinomas given treatment with temozolomide.
    Bengtsson D; Schrøder HD; Andersen M; Maiter D; Berinder K; Feldt Rasmussen U; Rasmussen ÅK; Johannsson G; Hoybye C; van der Lely AJ; Petersson M; Ragnarsson O; Burman P
    J Clin Endocrinol Metab; 2015 Apr; 100(4):1689-98. PubMed ID: 25646794
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Temozolomide in the treatment of an invasive prolactinoma resistant to dopamine agonists.
    Neff LM; Weil M; Cole A; Hedges TR; Shucart W; Lawrence D; Zhu JJ; Tischler AS; Lechan RM
    Pituitary; 2007; 10(1):81-6. PubMed ID: 17285366
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pituitary apoplexy during therapy with cabergoline in an adolescent male with prolactin-secreting macroadenoma.
    Knoepfelmacher M; Gomes MC; Melo ME; Mendonca BB
    Pituitary; 2004; 7(2):83-7. PubMed ID: 15761656
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pituitary carcinoma - case series and review of the literature.
    Du Four S; Van Der Veken J; Duerinck J; Vermeulen E; Andreescu CE; Bruneau M; Neyns B; Velthoven V; Velkeniers B
    Front Endocrinol (Lausanne); 2022; 13():968692. PubMed ID: 36157469
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Correlation of scintigraphic results using 123I-methoxybenzamide with hormone levels and tumor size response to quinagolide in patients with pituitary adenomas.
    Ferone D; Lastoria S; Colao A; Varrella P; Cerbone G; Acampa W; Merola B; Salvatore M; Lombardi G
    J Clin Endocrinol Metab; 1998 Jan; 83(1):248-52. PubMed ID: 9435450
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Aggressive Pituitary Adenomas: The Dark Side of the Moon.
    Priola SM; Esposito F; Cannavò S; Conti A; Abbritti RV; Barresi V; Baldari S; Ferraù F; Germanò A; Tomasello F; Angileri FF
    World Neurosurg; 2017 Jan; 97():140-155. PubMed ID: 27713064
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.